de Thé G, Bomford R, Kazanji M, Ibrahim F
Département des Rétrovirus, Institut Pasteur, Paris, France.
Ciba Found Symp. 1994;187:47-55; discussion 55-60. doi: 10.1002/9780470514672.ch4.
Human T cell lymphotropic virus types I and II (HTLV-I/II) are endemic in certain areas of the world. They cause two life-threatening diseases, adult T cell leukaemia/lymphoma and tropical spastic paraparesis. A vaccine is needed because in developing countries there are no other feasible preventive interventions against these diseases and in Western countries intravenous drug users at high risk for HTLV-I and HTLV-II infections and the health workers in contact with such populations must be protected. We have developed a rat model in which we observed variations of susceptibility to viral infection between inbred strains, the most susceptible being the Fischer F344, and the possibility of viral latency in the nervous system. We have prepared a recombinant adenovirus vector that expresses the HTLV-I envelope glycoprotein env in HeLa cells. A target human population in French Guyana, in which the prevalence rate reaches 5.6% in one ethnic group (Bonis), has been identified for possible intervention.
人类嗜T细胞病毒I型和II型（HTLV-I/II）在世界某些地区呈地方性流行。它们会引发两种危及生命的疾病，即成人T细胞白血病/淋巴瘤和热带痉挛性截瘫。由于在发展中国家没有针对这些疾病的其他可行预防干预措施，并且在西方国家，感染HTLV-I和HTLV-II风险较高的静脉吸毒者以及接触此类人群的医护人员必须得到保护，因此需要一种疫苗。我们建立了一个大鼠模型，在该模型中我们观察到近交系之间对病毒感染的易感性存在差异，其中最易感的是Fischer F344，并且还观察到病毒在神经系统中潜伏的可能性。我们制备了一种重组腺病毒载体，该载体在HeLa细胞中表达HTLV-I包膜糖蛋白env。已确定法属圭亚那的一个目标人群可能需要干预，在该人群的一个族群（博尼斯人）中患病率达到5.6%。
